VahatiCor Enrolls First US Patient in Groundbreaking Clinical Study SERRA-I

VahatiCor Enrolls First U.S. Patient in SERRA-I Clinical Study

In a significant milestone for coronary microvascular dysfunction (CMD) treatments, VahatiCor, Inc. has announced the enrollment of its first U.S. patient in the SERRA-I clinical study. This study aims to evaluate the effectiveness of the A-FLUX Reducer System, a self-expanding device designed to improve blood flow in patients suffering from CMD, a condition that affects millions but currently lacks approved treatments in the U.S.

The A-FLUX Reducer System is at the forefront of clinical innovation, marking the beginning of SERRA-I's evaluation phase in the U.S. This device is designed to be placed in the coronary sinus via catheter, allowing for better management of blood flow through the heart's smallest vessels. As CMD causes persistent angina and chest pain without significant obstructions in the main coronary arteries, the need for effective interventions has never been more pressing.

The enrollment took place at Yale-New Haven Hospital under the supervision of Dr. Samit Shah, a leading interventional cardiologist and co-investigator of the SERRA-I study. Dr. Shah emphasized the importance of this moment, stating, "The treatment of our first patient introduces the A-FLUX system to clinical research in the United States, marking a pivotal step toward addressing CMD as a frontline cardiovascular disease."

VahatiCor's CEO, Dr. Harry D. Rowland, echoed this sentiment, highlighting the advancements in cardiology towards systemic treatment for microvascular disease. "We are grateful to the investigators and patients who are making the SERRA-I study possible, as they play a crucial role in the advancement of healthcare solutions for CMD."

CMD is characterized by its complex and often debilitating symptoms, which can significantly impact a patient's quality of life. However, conventional therapies have fallen short for many of these individuals, with no approved options directly addressing the underlying microvascular issues. Dr. Shah further reinforced the urgent need for evidence-based treatment options for CMD, noting that the enrollment of the first U.S. patient represents a critical step towards validating the efficacy of the A-FLUX Reducer System.

VahatiCor, part of T45 Labs, is committed to harnessing innovative technologies to combat CMD, a prevalent condition affecting those with unexplained cardiovascular symptoms. The A-FLUX Reducer System is the company’s flagship technology, currently in clinical evaluation as part of the SERRA program, which spans both the United States and the European Union.

Based in Santa Clara, California, VahatiCor is poised to lead advancements in this vital area of cardiac health. As the evaluation continues, the medical community and patients alike are hopeful for successful outcomes from the SERRA-I trial, which could open new avenues for treating CMD effectively.

For ongoing updates and details about the study, please visit VahatiCor's official website. Please note that the A-FLUX Reducer System is an investigational device and has not yet received approval from the U.S. FDA for commercial use.